title: Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells.
abstract: Stathmin gene overexpression has been shown to play an important role in maintenance of malignant phenotype in tumor cells, and the blocking efficacy and tumor specificity of this target has been concerned in clinical trails. In this report, we designed survivin promoter-driven siRNA eukaryotic expression vector that expressed the small interfering RNA targeting stathmin gene to selectively knock down the stathmin gene expression in two different kinds of tumor cell lines while sparing normal cell lines. The therapeutic potential of this recombinant vector was tested in human cervical cancer Hela cells and osteosarcoma SSOP-9607 cells, and in human umbilical vein endothelial cell line ECV304 cells as control. The siRNA vector- transfected Hela cells and SSOP-9607 cells revealed marked inhibition of stathmin expression and a dramatic growth inhibition comparing with ECV304 cells, parental-vector transfected cells and untransfected cells. Cell cycle analysis of siRNA vector transfected tumor cells by Flow Cytometry showed G(2)/M phase block, while morphologic analysis by TURNEL staining method showed marked increase of apoptosis. Our study indicates that survivin gene promoter-driven stathmin siRNA expression vector may have potential use in tumor gene therapy with targeted tumor gene silencing effect.
authors.affiliation: Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. huizhong@public.xa.sn.cn <huizhong@public.xa.sn.cn>
authors.forename: Hui-Zhong
authors.initials: HZ
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Ping
authors.initials: P
authors.lastname: Gao
authors.forename: Fang
authors.initials: F
authors.lastname: Lin
authors.forename: Li
authors.initials: L
authors.lastname: Liu
authors.forename: Bing
authors.initials: B
authors.lastname: Yu
authors.forename: Ji-Hong
authors.initials: JH
authors.lastname: Ren
authors.forename: Hui
authors.initials: H
authors.lastname: Zhao
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
mesh_terms: D017209:Apoptosis; D001859:Bone Neoplasms; D002455:Cell Division; D002460:Cell Line; D045744:Cell Line, Tumor; D017931:DNA Primers; D004730:Endothelium, Vascular; D020868:Gene Silencing; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006367:HeLa Cells; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000235:genetics*; D009363:Neoplasm Proteins / Q000235:genetics*; D012516:Osteosarcoma; D010957:Plasmids; D011401:Promoter Regions, Genetic; D034741:RNA, Small Interfering / Q000235:genetics*; D015183:Restriction Mapping; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050777:Stathmin / Q000235:genetics*; D000077022:Survivin; D014162:Transfection; D014471:Umbilical Veins
chemical_list: C107489:BIRC5 protein, human; D017931:DNA Primers; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D034741:RNA, Small Interfering; D050777:Stathmin; D000077022:Survivin